167 related articles for article (PubMed ID: 8373757)
1. New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
Li XM; Juorio AV; Paterson IA; Boulton AA
J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757
[No Abstract] [Full Text] [Related]
2. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
3. MAO type B inhibitors as adjunct to L-dopa therapy.
Youdim MB; Finberg JP
Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
[No Abstract] [Full Text] [Related]
4. MAO-B inhibitors in Parkinson's disease.
Olanow CW
Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
[No Abstract] [Full Text] [Related]
5. Critical role of MAO inhibition in Parkinson's disease.
Knoll J
Adv Neurol; 1987; 45():107-10. PubMed ID: 3103382
[No Abstract] [Full Text] [Related]
6. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
7. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
9. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
10. Are there MAO inhibitors specific for dopamine metabolism?
Youdim MB; Holzbauer M
Adv Biochem Psychopharmacol; 1977; 16():349-58. PubMed ID: 329649
[No Abstract] [Full Text] [Related]
11. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
12. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
Lew MF
Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328
[TBL] [Abstract][Full Text] [Related]
13. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
LeWitt PA
Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
[No Abstract] [Full Text] [Related]
14. Selegiline HC1: Selective MAO-type B inhibitor.
Koller WC; Giron LT
Neurology; 1990 Oct; 40(10 Suppl 3):suppl 58-60. PubMed ID: 2120616
[No Abstract] [Full Text] [Related]
15. [Neuroprotective and neurorestorative therapy in Parkinson's disease].
Jiménez-Jiménez FJ; Molina JA
Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687
[TBL] [Abstract][Full Text] [Related]
16. MAO inhibitors.
Keller D
Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
[No Abstract] [Full Text] [Related]
17. Other pharmacological treatments for motor complications and dyskinesias.
Waters C
Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease.
Imke S
Adv Nurse Pract; 1998 Jan; 6(1):24-8. PubMed ID: 9495941
[No Abstract] [Full Text] [Related]
19. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H
Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285
[No Abstract] [Full Text] [Related]
20. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]